Case Of Ovarian Carcinosarcoma Research Articles

Ovarian carcinosarcoma with lung metastasis characterized by persistent fever: A case report and literature review.

Ovarian carcinosarcoma (OCS) is a rare malignant tumor prone to distant metastasis. Primary manifestations include pelvic and/or abdominal pain, bloating, and compression. Nevertheless, it is uncommon for OCS to present primarily with persistent fever. This is the first reported case of OCS with lung metastasis characterized by persistent fever. A 61-year-old female patient complaining of abdominal pain and fever was admitted to our hospital. Computed tomography showed an irregular, slightly low-density mass on the left side of the uterus and multiple solid nodules in both lungs. She underwent cytoreductive surgery for pathologically confirmed stage IVB OCS. She was administered chemotherapy after cytoreductive surgery. Given the patient's history of persistent fever and progressively enlarged pulmonary nodules, a pulmonary abscess was considered as a possible diagnosis. Following antibiotic therapy, the patient's high body temperature did not decrease; however, following nonsteroidal anti-inflammatory drug therapy, it quickly decreased. These symptoms were eventually considered the consequence of neoplastic fever caused by lung metastases. Owing to the rapid progression of the disease, the patient ultimately died. This study suggests that, for patients with pelvic and/or abdominal pain, bloating, and pelvic masses, especially those with suspicious lesions in other organs accompanied by fever of unknown origin, a diagnosis of cancer or sarcoma with metastasis should be considered after ruling out infectious fever.

EP42.24: Two cases of ovarian carcinosarcoma with initial ultrasonographic diagnosis of malignant tumour of non‐ovarian origin

EP42.24: Two cases of ovarian carcinosarcoma with initial ultrasonographic diagnosis of malignant tumour of non‐ovarian origin

OVARIAN CARCINOSARCOMA: A RARE CASE OF GYNECOLOGIC MALIGNANCY

Carcinosarcoma is a type of mixed malignant biphasic tumour which represents a rare entity and comprises both epithelial and mesenchymal components. It is a rare disease entity that accounts for 1-4% of all ovarian tumours. Presented in this paper is a case of gynecologic malignancy which is the ovarian carcinosarcoma which is of rare occurrence. A case of ovarian carcinosarcoma is elucidated in this paper as it discusses its clinicopathological characteristics and assesses the prognostic factors associated with treatment outcome and survival. A 62-year old woman presented with a 2-month history of abdominal enlargement, dyspnea, feeling of bloatedness and marked weight loss. Series of diagnostic examinations and procedures were done and of different impressions that have made the case of difficult diagnostic dilemma. The patient was initially diagnosed as a case Anaplastic carcinoma, who eventually underwent exploratory Laparotomy and left salpingo-oophorectomy wherein biopsy revealed poorly differentiated malignancy with primary consideration of Undifferentiated pleomorphic sarcoma or Anaplastic carcinoma. The final diagnosis of which relied on the importance of immunohistochemical stains such as vimentin and cytokeratin to which vimentin yielded a positive result. A final diagnosis of ovarian carcinosarcoma was established. Due to the rare occurrence of ovarian carcinosarcoma, no standard treatment has yet been developed. Both primary and cytoreductive surgery and disease stages have been reported as significant prognostic factors. The treatment of such ovarian malignancy is optimal debulking surgery and chemotherapy either neoadjuvant or adjuvant.

Clinical Nomograms for Predicting the Overall Survival and Cancer-specific Survival of patients with Ovarian Carcinosarcoma patients after Primary Surgery.

Background: At present, there is no clinical prediction model for ovarian carcinosarcoma (OCS) that is based on a large sample of real data. This study aimed to construct nomograms using data extracted from the Surveillance, Epidemiology, and End Results (SEER) database that can be used to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with OCS and further guide the choice of clinical treatment.Methods: We selected 2753 cases of OCS from the SEER database from 1998 to 2016. Patients were randomly divided in a 7:3 ratio into a training cohort (n = 1929) and a validation cohort (n = 824). Cox analysis was used to select prognostic factors for OS and CSS, and nomograms were then established. The performance of nomogram models was assessed using the concordance index, the area under the receiver operating characteristic curve, calibration curves, and by decision curve analysis. Data from 21 OCS patients at Shengjing Hospital from 2001 to 2021 were collected for external verification. Kaplan-Meier curves were plotted to compare survival outcomes between subgroups.Results: Nomograms based on independent prognostic factors showed good predictive power and clinical practicality. Internal and external validation indicated that the nomograms performed better than staging and grading systems. Significant differences were observed in the survival curves of different risk subgroups.Conclusions: The developed nomograms will enable individualized evaluation of the OS and CSS, thus guiding the treatment of patients with OCS.

A rare case of ovarian carcinosarcoma with squamous cell carcinoma

BackgroundOvarian carcinosarcoma, which contains sarcomatous and carcinomatous components, is a very rare tumor. The carcinomatous component is often adenocarcinoma, and squamous cell carcinoma is extremely rare. We herein report a case of ovarian carcinosarcoma in which the carcinomatous component was squamous cell carcinoma.Case presentationA 68-year-old woman presented with a huge ovarian tumor with a clinical diagnosis of malignant tumor of the ovary. She underwent hysterectomy, bilateral adnexectomy, omentectomy and lymphadenectomy. Histologically, the tumor cells showed undifferentiated pleomorphic sarcoma as the sarcomatous component and squamous cell carcinoma as the carcinomatous component. The final diagnosis was ovarian carcinosarcoma with squamous cell carcinoma in the carcinomatous component, stage IIIA1. Postoperatively, the patient was treated with six cycles of combination chemotherapy with paclitaxel and carboplatin as adjuvant therapy. The patient was free of disease at 45 months’ follow-up consultation.ConclusionThis is a rare report of ovarian carcinosarcoma with an epithelial component composed of squamous cell carcinoma. Combination chemotherapy with paclitaxel and carboplatin may be an effective choice as adjuvant chemotherapy in cases of ovarian carcinosarcoma including squamous cell carcinoma.

Carcinosarcoma of the ovary successfully treated with paclitaxel and carboplatin therapy: two cases

We present two rare cases of carcinosarcoma of the ovary treated successfully with paclitaxel and carboplatin therapy. Case 1: A 79-year-old Japanese woman was diagnosed with carcinosarcoma of the ovary stage IV. We administered neoadjuvant chemotherapy (paclitaxel 180 mg/m2 and carboplatin AUC 6). After three cycles, she underwent a bilateral salpingo-oophorectomy, hysterectomy and omentectomy as a debulking procedure. She received another three cycles of paclitaxel and carboplatin therapy as adjuvant therapy. She is well without evidence of disease 6 months after the sixth chemotherapy cycle. Case 2: A 74-year-old Japanese woman was diagnosed with carcinosarcoma of the ovary stage IIIc. We performed hysterectomy, bilateral salpingo-oophorectomy, partial resection of small intestine, pelvic lymphadenectomy, omentectomy and low anterior resection of the rectosigmoid colon as the primary debulking surgery. She received six cycles of paclitaxel and carboplatin therapy as adjuvant therapy. She has been recurrence free for 6 years. The standard chemotherapy for ovarian carcinosarcoma is not established, but we think that paclitaxel and carboplatin therapy for progressive ovarian carcinosarcoma as an adjuvant therapy might become a standard chemotherapy if further cases of ovarian carcinosarcoma treated with paclitaxel and carboplatin therapy are reported.

Rhabdomyosarcoma with Pseudolipoblasts Arising in Ovarian Carcinosarcoma: A Distinctive Postchemotherapy Morphologic Variant Mimicking Pleomorphic Liposarcoma

We describe a case of ovarian carcinosarcoma occurring in a 60-year-old female. The neoplasm was excised after neoadjuvant chemotherapy and contained a predominant heterologous pleomorphic rhabdomyosarcomatous component in which there were numerous multivacuolated rhabdomyoblasts that strongly mimicked lipoblasts. The clear cell variant of rhabdomyosarcoma is rarely documented, but this case shows a highly unusual finding in which the rhabdomyoblasts show the prominent multivacuolation with nuclear indentation characteristic of and indistinguishable from pleomorphic lipoblasts. This appears to represent a posttreatment phenomenon. As this finding might conceivably occur in other rhabdomyosarcomas after chemotherapy, we highlight the potential for diagnostic confusion with pleomorphic liposarcoma, which is usually diagnosed by morphology so that immunohistochemistry for muscle markers might not be performed.